EventsThe 5th International Electronic Conference on Brain Sciences & 1st International Electronic Conference on Neurosciences
Published
This submission belongs to the session S1. Neurodegenerative Diseases of the event The 5th International Electronic Conference on Brain Sciences & 1st International Electronic Conference on Neurosciences
Published date
04 Mar, 2026
Academic Editor
author-avatarGrazyna Lietzau
Citation
Alan Michael Palmer, The Cerebrocortical Disconnection Hypothesis: Reframing Alzheimer's Treatment Strategy, in Proceedings of The 5th International Electronic Conference on Brain Sciences & 1st International Electronic Conference on Neurosciences, 9 March–11 March 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

The Cerebrocortical Disconnection Hypothesis: Reframing Alzheimer's Treatment Strategy

1. Elixa MediScience Limited, 24-28 Brockenhurst Road, Ascot, Berkshire, SL5 9DL, UK, UK
Abstract

Alzheimer's disease (AD), the most common cause of dementia, is defined by amyloid plaques, neurofibrillary tangles (NFTs) of hyperphosphorylated tau, and neuronal loss. The traditional amyloid cascade hypothesis long held that amyloid-β (Aβ) accumulation is the primary instigating event, supported by early genetic evidence linking AD to mutations in Aβ-processing genes (APP, PSEN1/2).

However, this paradigm is challenged by clinical trial results. Approved anti-Aβ immunotherapies, despite significantly reducing plaque levels, confer only modest clinical benefits, slowing cognitive decline slightly. Tau-based therapies have also failed, though they have not yet successfully cleared NFTs from the perikarya of cortical pyramidal neurons.

This evidence supports a proposed shift to the cerebrocortical disconnection hypothesis. This theory posits that dementia results from the breakdown of neural networks, initiated when tau aggregates into NFTs. This disruption damages axonal transport, creating an energetic crisis at nerve terminals, which promotes the production of Aβ42 and subsequent amyloid plaque formation.

The neural breakdown is further worsened by the dysfunction and loss of myelin-maintaining oligodendrocytes, leading to demyelination. This forces the damaged axons to expend even more energy for signalling, severely exacerbating their bioenergetic deficit. This combination of faulty transport, amyloid pathology, and myelin loss ultimately destroys critical long corticocortical and corticofugal neurons, along with (cholinergic, noradrenergic and serotonergic) corticopetal neurons. We conclude that therapeutic focus must now shift toward protecting the integrity of neural circuitry directly to prevent disconnection and meaningfully slow cognitive decline.

Keywords
Alzheimer’s disease
biomarkers
blood-brain barrier
clinical trials
dementia
disease-modification
drug development
immunotherapy
medicines
neurodegeneration.
Proteomic Profiling Reveals Systemic Effects of Peripheral mHtt Expression in Huntington’s Disease
Toward Reproducibility in Preclinical Alzheimer’s Research: The Case for Standardizing Aβ₁–₄₂-Induced Rodent Models